QUINCE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.06 USD | +2.91% |
|
+0.95% | +0.95% |
| Apr. 01 | Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 26 | Transcript : Quince Therapeutics, Inc. - Special Call |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 1,507 | 819.5 | 377.1 | 23.03 | 45.01 |
| Enterprise Value (EV) 1 | 1,408 | 686.1 | 271.4 | -66.7 | -16.23 |
| P/E ratio | -28.9 x | -10.5 x | -4.17 x | -0.41 x | -1.25 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | -36.1 x | -8.73 x | -3.02 x | 1.34 x | 0.67 x |
| EV / FCF | -69.8 x | -28 x | -8.89 x | 2.76 x | 8.36 x |
| FCF Yield | -1.43% | -3.58% | -11.3% | 36.3% | 12% |
| Price to Book | 13.1 x | 4.76 x | 3.2 x | 0.23 x | 0.53 x |
| Nbr of stocks (in thousands) | 26,852 | 29,498 | 29,878 | 36,130 | 42,869 |
| Reference price 2 | 56.14 | 27.78 | 12.62 | 0.6374 | 1.050 |
| Announcement Date | 3/16/20 | 3/1/21 | 3/1/22 | 3/15/23 | 4/1/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -12.07 | -38.98 | -78.56 | -89.97 | -49.89 | -24.32 |
| EBIT 1 | -12.12 | -39.17 | -78.89 | -90.32 | -50.09 | -24.64 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -12.48 | -36.98 | -76.85 | -89.94 | -51.94 | -31.58 |
| Net income 1 | -12.48 | -36.98 | -76.85 | -89.94 | -51.66 | -31.38 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -3.711 | -1.943 | -2.634 | -3.027 | -1.542 | -0.8428 |
| Free Cash Flow 1 | -8.464 | -20.18 | -24.54 | -30.54 | -24.18 | -1.941 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/4/19 | 3/16/20 | 3/1/21 | 3/1/22 | 3/15/23 | 4/1/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA 1 | -21.59 | -23.46 | -21.82 | -16.17 |
| EBIT 1 | -21.68 | -23.54 | -21.86 | -16.26 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | -21.71 | -23.4 | -21.64 | -16.85 |
| Net income 1 | -21.71 | -23.4 | -21.64 | -16.56 |
| Net margin | - | - | - | - |
| EPS 2 | -0.7300 | -0.7800 | -0.7200 | -0.5100 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 10/29/21 | 3/1/22 | 5/10/22 | 8/9/22 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 71.7 | 99.9 | 133 | 106 | 89.7 | 61.2 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -8.46 | -20.2 | -24.5 | -30.5 | -24.2 | -1.94 |
| ROE (net income / shareholders' equity) | -36.5% | -39.6% | -53.4% | -61.9% | -47.1% | -33.8% |
| ROA (Net income/ Total Assets) | -18.8% | -24.8% | -31.4% | -35% | -26.4% | -11.3% |
| Assets 1 | 66.38 | 149 | 244.6 | 257.1 | 195.7 | 277 |
| Book Value Per Share 2 | -9.560 | 4.300 | 5.830 | 3.940 | 2.780 | 1.980 |
| Cash Flow per Share 2 | 7.290 | 1.910 | 2.260 | 2.320 | 1.230 | 0.4800 |
| Capex 1 | 0.21 | 0.06 | 0.05 | 0.18 | 0.13 | 0.16 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/4/19 | 3/16/20 | 3/1/21 | 3/1/22 | 3/15/23 | 4/1/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +0.95% | 45.81M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- QNCX Stock
- Financials Quince Therapeutics, Inc.
